Log in to search using one of your social media accounts:

 

VA, ASTRO and Washington U. combine forces to drive better care for veterans with cancer

(American Society for Radiation Oncology) The Department of Veterans Affairs today announced a new Radiation Oncology Practice Assessment program to leverage recent advances in information technology to improve radiation therapy cancer care for our nation's Veterans. VA is working with the American Society for Radiation Oncology and Washington University to provide radiation oncologists for the first time with continuous feedback on the progress of cancer therapy.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news

Related Links:

ConclusionsThe experimental results demonstrate that GNP-mediated chemoradiation has the potential to improve cancer care in the near future through enhancement of the local radiation dose and controlled delivery of anticancer drugs.
Source: Cancer Nanotechnology - Category: Cancer & Oncology Source Type: research
One major challenge in the development of effective cancer therapies is a lack of universal, cancer specific markers in target cells. The current standard therapies rely on surgery, chemotherapy, and radiation therapy. Such procedures lead to a population of resistant cancer cells that makes further applications of chemotherapy/radiation therapy ineffective. Additionally, the systemic application of chemotherapy lacks specificity and has   off-target systemic effects that lead to adverse side effects. A considerable effort has been devoted to identifying and targeting specific extracellular cancer markers using antibo...
Source: NIH OTT Licensing Opportunities - Category: Research Authors: Source Type: research
Abstract Medical oncology is in need of a mathematical modeling toolkit that can leverage clinically-available measurements to optimize treatment selection and schedules for patients. Just as the therapeutic choice has been optimized to match tumor genetics, the delivery of those therapeutics should be optimized based on patient-specific pharmacokinetic/pharmacodynamic properties. Under the current approach to treatment response planning and assessment, there does not exist an efficient method to consolidate biomarker changes into a holistic understanding of treatment response. While the majority of research on ch...
Source: Translational Oncology - Category: Cancer & Oncology Authors: Tags: Transl Oncol Source Type: research
Publication date: February 2018 Source:Clinical Plasma Medicine, Volume 9, Supplement Author(s): Endre Szili, Jun-Seok Oh, Hideo Fukuhara, Keiji Inoue, Akimitsu Hatta, Rob Short A challenge in cancer therapy is the destruction of tumours, where there is the potential issue of cancer cells residing within hypoxic tissue. The concept of hypoxic regions within tumours dates back to 1909 and it has long been suspected that under low oxygen tension, cells are “afforded” radiation protection. It has been shown many decades ago, that raising the concentration of oxygen in tissues can significantly improve the outcome...
Source: Clinical Plasma Medicine - Category: Research Source Type: research
Publication date: February 2018 Source:Clinical Plasma Medicine, Volume 9, Supplement Author(s): Eric Freund, Christine Hackbarth, Lars-Ivo Partecke, Sander Bekeschus Diffuse peritoneal metastasis of gastrointestinal tumors is a life-threatening complication in end-stage tumor patients. Standard of care is hyperthermic intraperitoneal chemotherapy (HIPEC) and/or radiation therapy, both associated with significant side effects [1]. Previous studies have suggested that cold physical plasma may present a new anti-tumor tool with few to none side effects [2]. Moreover, plasma-induced reactive species can be transferred to cel...
Source: Clinical Plasma Medicine - Category: Research Source Type: research
Varian Medical (NYSE:VAR) said today it launched an FDA-cleared version of its Velocity cancer imaging software, including a new Rapidsphere module. The newly launched Velocity 4.0’s Rapidsphere module is designed for Y90 selective internal radiation therapy dosimetry analysis and provides improved information on tumor responses and normal-tissue toxicity for patients undergoing SIRT, the Palo Alto, Calif.-based company said. The Velocity 4.0 software includes the company’s Velocity M3i multi-modality motion imaging component, the Velocity Aria sync component and the Velocity tumor &dose tracking compo...
Source: Mass Device - Category: Medical Devices Authors: Tags: Business/Financial News Imaging Oncology Software / IT Varian Medical Systems Source Type: news
For men diagnosed with aggressive cancer that’s confined to the prostate and nearby tissues, the overarching goal of treatment is to keep the disease from spreading (or metastasizing) in the body. Doctors can treat these men with localized therapies, such as surgery and different types of radiation that target the prostate directly. And they can also give systemic treatments that kill off rogue cancer cells in the bloodstream. Hormonal therapy, for instance, is a systemic treatment that kills prostate cancer cells by depriving them of testosterone, which fuels their growth. Now a new study shows that a mix of differe...
Source: Harvard Health Blog - Category: Consumer Health News Authors: Tags: Cancer Men's Health Prostate Health Source Type: blogs
High-frequency irreversible electroporation (H-FIRE) is an emerging cancer therapy, which uses bursts of short duration, alternating polarity, high-voltage electrical pulses to focally ablate tumors. Here, we present a preliminary investigation of the combinatorial effects of H-FIRE and ionizing radiation. In vitro cell cultures were exposed to bursts of 500 ns pulses and single radiation doses of 2 or 20 Gy then analyzed for 14 days. H-FIRE and radiation therapy (RT) appear to induce different delayed cell death mechanisms and in all treatment groups combinatorial therapy resulted in lower overall viabilities. T...
Source: IEEE Transactions on Biomedical Engineering - Category: Biomedical Engineering Source Type: research
Accumulating evidence suggests disagreement between clinician-observed and patient-reported symptoms associated with cancer therapy, but this discrepancy in an older population receiving definitive radiation therapy (RT) is not well-understood. The concordance between clinician- and patient-reported toxicities and their association with poor tolerance to treatment were assessed.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Source Type: research
Publication date: March 2018 Source:Colloid and Interface Science Communications, Volume 23 Author(s): Yue Pan, Peijun Xue, Shaopeng Liu, Lechuan Zhang, Qingbao Guan, Jianliang Zhu, Xin Tian Radiation therapy is one of the most commonly used interventions in cancer therapy. However, innate or acquired radioresistance in several cancers, and toxicity to normal tissues are still serious concerns. In order to enhance radiation response in cancer therapy, metal-based nanoparticles have been widely studied as the radiosensitizers. Recently, more and more studies have demonstrated the potential value of metal-based hybrid nanop...
Source: Colloids and Interface Science Communications - Category: Nanotechnology Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Information Technology | Radiation Therapy | Washington University